Abstract P063: A Systematic Review of Current Dietary Policies for Reducing Cardiometabolic Diseases in the Middle East
Background: Cardiometabolic diseases such as CVD and diabetes are rising rapidly in many regions, especially the Middle East. Governments could reduce these burdens by targeting suboptimal diets, but little is known about national dietary policies in this region.
Objective: To systematically investigate, summarize, and identify gaps in national dietary policies in 22 Middle Eastern nations.
Methods: Using PRISMA and MOOSE guidelines, we systematically searched PubMed, Econ Lit, PAIS, Cochrane library, AGRIS, Web of Science, CABI, and CINAHL for original studies, reviews, and organizational reports on national dietary policies adopted in these countries; Google searches are ongoing. We searched for dietary policies in 6 categories: media/education, labeling/consumer info, taxes/subsidies, school programs, workplace approaches, and direct bans/mandates. We evaluated 13 dietary targets of interest (Figure). Studies were excluded if published prior to 1980, described only local (subnational) policies, or only provided data on policies for food safety, micronutrient deficiency, hunger, or other issues without at least one focus on cardiometabolic risk.
Results: From 3866 identified studies, 17 met inclusion criteria. We found 4 types of dietary policies (media/education, labeling/consumer information, taxation/subsidies, direct bans/mandates) in 9 countries of the region (Bahrain, Djibouti, Egypt, Iran, Jordan, Kuwait, Pakistan, Sudan, United Arab Emirates) that targeted 7 dietary factors (fruits, vegetables, whole grains, unprocessed red meat, trans fats, sodium, dietary fiber) . Details of these policies will be presented, as well as current gaps (Figure).
Conclusions: Our findings highlight existing national dietary policies that have been adopted to reduce cardiometabolic diseases in the Middle East, as well as remaining major policy gaps, thereby identifying current progress and opportunities for policy innovation.
Author Disclosures: A. Afshin: None. S. Shangguan: None. M. Nomura-Baba: None. Y. Abu Awad: None. M. Reich: None. D. Mozaffarian: B. Research Grant; Significant; Research grants from GlaxoSmithKline, Sigma Tau, Pronova, and the National Institutes of Health for a completed investigator-initiated, not-for-profit, randomized clinical trial of fish oil suppleme. E. Honoraria; Modest; Ad hoc travel reimbursement and/or honoraria for one-time scientific presentations or reviews on diet and cardiometabolic diseases from Quaker Oats (4/12), Life Sciences Research Organization (10/12. G. Consultant/Advisory Board; Modest; Ad hoc consulting fees from McKinsey Health Systems Institute (11/11), Foodminds (1/12), Nutrition Impact (10/12), Amarin (9/13), Omthera (9/13), and Winston and Strawn LLP (9/13), Advisory board: Unilever North America Scientific Advisory Board. H. Other; Modest; Royalties from UpToDate, for an online chapter on fish oil, Patent: Harvard University has filed a provisional patent application, that has been assigned to Harvard University, listing Dr. Mozaffarian as a co-inventor to the US Patent and Trademark Office f.
- © 2014 by American Heart Association, Inc.